In today’s briefing:
- Honasa Consumer IPO – Thoughts on Valuations
- [Week 9] Namaste India 🙏 | Earnings Edition – Part II
- Bharat Petroleum – ESG Report – Lucror Analytics
- Dr. Reddy’s Laboratories (DRRD IN): Highest Ever Sales and Profit in Q2; Good Show in Key Markets
- Mankind Pharma Lock-Up – A US$1.1bn+ Lockup Release
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
Honasa Consumer IPO – Thoughts on Valuations
- Honasa Consumer is looking to raise about US$200m in its upcoming India IPO.
- HC’s product portfolio includes products in the baby care, face care, body care, hair care, color cosmetics and fragrances segments.
- In our previous note, we looked at the company’s past performance. In this note, we talk about the RHP updates and valuations.
[Week 9] Namaste India 🙏 | Earnings Edition – Part II
- Our earnings coverage continues for the second edition and is expected to continue for one more week.
- At the bottom, we provide a consolidated view of all earnings tracked so far (Bullish / Bearish) and would be happy to engage on any of them.
- We also highlight the earnings of some of the global companies that have significant operations or growth in India.
Bharat Petroleum – ESG Report – Lucror Analytics
Lucror Analytics’ ESG Scores are based on a 3-tiered scale and are adjusted for Controversies (if applicable).
We view Bharat Petroleum’s ESG as “Adequate”, in line with its Environmental, Social and Governance scores. Controversies are “Material”, but Disclosure is “Adequate”.
Dr. Reddy’s Laboratories (DRRD IN): Highest Ever Sales and Profit in Q2; Good Show in Key Markets
- Global generics revenue increased 9% YoY to INR61 billion, mainly driven by double-digit growth in North America and Europe generic businesses, partly offset by muted growth in domestic market.
- Revenue from North America generics increased 13% y/y to INR31.7 billion, driven by growing momentum in core portfolio, Mayne integration, and favorable Fx. Pricing environment remains stable.
- Despite increase in SG&A and R&D expenses, EBITDA grew 13% YoY to INR 21.8 billion. Net profit increased 33% YoY to INR14.8 billion. Both EBITDA and net profit topped estimates.
Mankind Pharma Lock-Up – A US$1.1bn+ Lockup Release
- A group of shareholders raised around US$530m in Mankind Pharma(MP) IPO in May 2023. The pre-IPO shareholders will be released from their lockup soon.
- MP is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
- In this note, we will talk about the lock-up dynamics and recent updates.